

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on OCTOBER 11, 2004.

Jenna M. Morrison
Jenna M. Morrison, Patent Attorney

JFW
INFORMATION DISCLOSURE
STATEMENT

Examining Group 1614

Patent Application

Docket No. USF-T195XC1

Serial No. 10/764,728

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1614
Applicants : Q. Ping Dou, Tak-Hang Chan, David M. Smith
Serial No. : 10/764,728
Filed : January 26, 2004
For : Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Jenna M. Morrison
Jenna M. Morrison

Patent Attorney

Registration No. 55,468

Phone No.: 352-375-8100


Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

JMM/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/764,728		
		Filing Date	January 26, 2004		
		First Named Inventor	Q. Ping Dou		
		Group Art Unit	1614		
		Examiner Name			
Sheet	1	of	1	Attorney Docket Number	USF-T195XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ADAMS, J. <i>et al.</i> "Proteasome inhibitors: A novel class of potent and effective antitumor agents" <i>Cancer Res.</i> , 1999, 59:2615-2622.	
	R2	ALMOND, J.B. and G.M. COHEN "The proteasome: a novel target for cancer chemotherapy" <i>Leukemia</i> , 2002, 16:433-443.	
	R3	DOU, Q.P. <i>et al.</i> "Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy" <i>Prog. Cell Cycle Res.</i> , 2003, 5:441-446.	
	R4	DOU, Q.P. and B. LI "Proteasome inhibitors as potential novel anticancer agents" <i>Drug Resis. Updates</i> , 1999, 2:215-223.	
	R5	KAZI, A. <i>et al.</i> "Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein" <i>Biochem. Pharm.</i> , 2003, 66:965-976.	
	R6	KAZI, A. <i>et al.</i> "A natural <i>musaceas</i> plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells" <i>Inter. J. Mol. Med.</i> , 2003, 12:879-887.	
	R7	KISSELEV, A. and A.L. GOLDBERG "Proteasome inhibitors: from research tools to drug candidates" <i>Chem. & Biol.</i> , 2001, 8:739-758.	
	R8	LI, B. and Q.P. DOU "Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression" <i>PNAS</i> , 2000, 97(8):3850-3855.	
	R9	NAM, S. <i>et al.</i> "Ester bond-containing tea polyphenols potently inhibit proteasome activity <i>in vitro</i> and <i>in vivo</i> " <i>J. Biol. Chem.</i> , 2001, 276:13322-13330.	
	R10	PAGANO, M. <i>et al.</i> "Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27" <i>Science</i> , 1995, 269:682-685.	
	R11	VERMA, I.M. <i>et al.</i> "Rel/NF- κ B/I κ B family: intimate tales of association and dissociation" <i>Genes & Devel.</i> , 1995, 9:2723-2735.	
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.